Mupirocin-Iodophor ICU Decolonization Swap Out Trial

a study on Staphylococcus Aureus

Summary

at Riverside, California and other locations
study started
estimated completion

Description

Summary

The Swap Out Trial is a cluster randomized controlled trial of HCA hospitals, evaluating the non-inferiority of two decolonization regimens: Arm 1 Routine Care: ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing; Arm 2 Intervention: ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing Note: that enrolled "subjects" represents 137 individual HCA Hospitals (representing ~235 ICUs) that have been randomized.

Official Title

Cluster-randomized Non-inferiority Trial Comparing Mupirocin vs Iodophor for Nasal Decolonization of ICU Patients to Assess Impact on S. Aureus Clinical Cultures and All-cause Bloodstream Infection During Routine Chlorhexidine Bathing

Keywords

Staphylococcus AureusMRSAhealthcare-associated infectionsmupirociniodophorresistanceChlorhexidineChlorhexidine gluconateArm 1. Routine Care (Mupirocin/CHG)Arm 2. Iodophor/CHG Decolonization

Eligibility

You can join if…

  • Inclusion criteria includes all U.S. HCA hospitals with an adult ICU;
  • Note: Unit of randomization is the hospital, but the participants are hospital adult ICUs
  • All patients within adult ICUs are included, including rare patients <18 years and >=12 years.

You CAN'T join if...

  • Exclusion criteria includes ICUs with an average length of stay of less than 2 days;
  • HCA hospitals that are not able to transfer or merge data into the centralized data warehouse for the baseline and intervention periods of the study are also excluded.

Locations

  • Riverside Community Hospitalaccepting new patients
    RiversideCalifornia92501United States
  • West Hills Hospital & Medical Centeraccepting new patients
    West HillsCalifornia91307United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Harvard Pilgrim Health Care
ID
NCT03140423
Phase
Phase 4
Study Type
Interventional
Last Updated